280 related articles for article (PubMed ID: 31837932)
21. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
23. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
24. Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis.
Barreta A; Sarian L; Ferracini AC; Eloy L; Brito ABC; de Angelo Andrade L; Derchain S
Int J Gynecol Cancer; 2018 Sep; 28(7):1251-1257. PubMed ID: 30142123
[TBL] [Abstract][Full Text] [Related]
25. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
26. [Risk factors of endometriosis associated ovarian carcinoma in women aged 45 years and older].
He ZX; Wang S; Li ZF; Zhu L; Leng JH; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):314-319. PubMed ID: 28545269
[No Abstract] [Full Text] [Related]
27. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
28. Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis.
Lu J; Tao X; Zhou J; Lu Y; Wang Z; Liu H; Xu C
Oncotarget; 2017 Jan; 8(4):5843-5852. PubMed ID: 27992377
[TBL] [Abstract][Full Text] [Related]
29. Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study.
Tranoulis A; Buruiana FH; Gupta B; Kwong A; Lakhiani A; Yap J; Balega J; Singh K
Arch Gynecol Obstet; 2022 May; 305(5):1279-1289. PubMed ID: 34468823
[TBL] [Abstract][Full Text] [Related]
30. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study.
Scarfone G; Bergamini A; Noli S; Villa A; Cipriani S; Taccagni G; Vigano' P; Candiani M; Parazzini F; Mangili G
Gynecol Oncol; 2014 Jun; 133(3):480-4. PubMed ID: 24642093
[TBL] [Abstract][Full Text] [Related]
32. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
33. [Ovarian clear cell carcinoma derived from endometriotic cyst: a clinicopathological analysis of 54 cases].
Zhu Q; Lu Y; Rao Y; Ning Y; Qu Y; Wang L; Zhou X
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):838-42. PubMed ID: 26887772
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
[TBL] [Abstract][Full Text] [Related]
35. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort.
Sun M; Jiang W
Discov Oncol; 2023 Apr; 14(1):39. PubMed ID: 37004660
[TBL] [Abstract][Full Text] [Related]
36. Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Gadducci A; Notarnicola M; Menichetti A; Lanfredini N; Fanucchi A; Cosio S
Eur J Gynaecol Oncol; 2016; 37(2):182-8. PubMed ID: 27172742
[TBL] [Abstract][Full Text] [Related]
37. Patterns of palliative care referral in ovarian cancer: A single institution 5 year retrospective analysis.
Nitecki R; Diver EJ; Kamdar MM; Boruta DM; Del Carmen MC; Clark RM; Goodman A; Schorge JO; Growdon WB
Gynecol Oncol; 2018 Mar; 148(3):521-526. PubMed ID: 29395315
[TBL] [Abstract][Full Text] [Related]
38. Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience.
Mangili G; Bergamini A; Taccagni G; Gentile C; Panina P; Viganò P; Candiani M
Gynecol Oncol; 2012 Sep; 126(3):403-7. PubMed ID: 22609111
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
40. Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).
Marchetti C; Ferrandina G; Cormio G; Gambino A; Cecere S; Lorusso D; De Giorgi U; Bogliolo S; Fagotti A; Mammoliti S; Narducci F; Bergamini A; Scollo P; Biglia N; Breda E; Tamberi S; Marinaccio M; Angioli R; Salerno L; Eusebi MC; Loizzi V; Scambia G; Panici PB
Gynecol Oncol; 2016 Dec; 143(3):532-538. PubMed ID: 27717490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
